vildagliptin sold brand name galvus others oral antihyperglycemic agent antidiabetic drug dipeptidyl inhibitor class drugs vildagliptin inhibits inactivation allowing gip potentiate secretion insulin beta cells suppress glucagon release alpha cells islets langerhans pancreas vildagliptin shown reduce hyperglycemia type diabetes european medicines agency also approved combination vildagliptin metformin vildagliptinmetformin eucreas novartis oral treatment adverse effects observed clinical trials include nausea hypoglycemia tremor headache dizziness rare cases hepatoxicity case reports pancreatitis associated inhibitors group ucla reported increased precancerous pancreatic changes rats human organ donors treated response reports united states fda european medicines agency undertook independent reviews clinical preclinical data related possible association inhibitors pancreatic cancer joint letter new england journal medicines agencies stated agencies agree assertions concerning causal association incretinbased drugs pancreatitis pancreatic cancer expressed recently scientific literature media inconsistent current data fda ema reached final conclusion time regarding causal relationship although totality data reviewed provides reassurance pancreatitis continue considered risk associated drugs data available agencies continue investigate safety httpsenwikipediaorgwikivildagliptin